NPY and hypertensive disorder: The major findings of this experiment demonstrate that (1) EA intervention effectively reduces arterial BP, (2) EA treatment attenuates increased blood pressure in 2K1C rats associated with a reduction in markers of sympathetic vasomotor activity, (3) EA stimulating remarkably improves baroreflex sensitivity in 2K1C rats, and (4) EA treatment increases the NPY mRNA and protein expression in the PVN and enhances the responses of PVN microinjection with NPY Y1R antagonist BIBO3304 in 2K1C hypertension rats.